Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

Prior treatment

• Prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)

Other illness

• Participants with history of (non-infectious) ILD/pneumonitis that required steroids or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
• Participants with non-healing wound, active ulcer, or bone fracture

Other

• Participants with tumours of non-epithelial origin, borderline tumours, or low-grade epithelial tumours.
• Participants with evidence of active or ongoing bowel obstruction

• Participants with newly diagnosed FIGO Stage III/IV, histologically confirmed epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma
• Provision of an archival FFPE tumour sample
• Participants who have completed at least 6 cycles and a maximum of 8 cycles of first-line Platinum-based chemotherapy (PBC) prior to randomisation
• Participants must have received a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of PBC, prior to randomisation
• Participants who have completed cytoreductive surgery or have inoperable disease
• Participants with non-progressive disease upon completion of front-line induction therapy
• HRD negative tumour